Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Yahoo! Finance
Royalty Revenue: $24.4 million in Q3 2024, compared to $2.7 million in Q2 2024 and $4.5 million in Q3 2023. Net Income (GAAP): $20.3 million or $0.41 per share for Q3 2024. Net Income (Non-GAAP): $22.4 million or $0.45 per diluted share for Q3 2024. Gross Revenue from N Excels: $67.7 million in Q3 2024. Gross to Net Adjustment: 17.1% in Q3 2024, down from 20.4% in Q2 2024. Cash and Equivalents: Approximately $97 million as of September 30, 2024. Cash Burn: Approximately $0.1 million in Q3 2024. Outstanding Principal Debt: Approximately $78.1 million as of September 30, 2024. SG&A Expenses: $16.9 million in Q3 2024, down from $25 million in Q2 2024. R&D Expenses: $12.5 million in Q3 2024, down from $13.6 million in Q2 2024. Warning! GuruFocus has detected 4 Warning Signs with PBYI. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Puma Biotechnology Inc ( NASDAQ:PBYI ) reported
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerBusiness Wire
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative [Yahoo! Finance]Yahoo! Finance
PBYI
Earnings
- 11/7/24 - Beat
PBYI
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- PBYI's page on the SEC website